Cytosorbents (CTSO) Operating Margin (2011 - 2026)
Cytosorbents (CTSO) posted Operating Margin of 34.34% for Q1 2026, up 27.68% on a QoQ basis from 47.49% in Q4 2025, and up 1021.0% year-over-year from 3.06% in Q1 2025.
Cytosorbents (CTSO) Operating Margin (2011 - 2026) Analysis & Trends
Cytosorbents' Operating Margin history runs 16 years deep, the most recent figure standing at 34.34% for Q1 2026.
- Quarterly Operating Margin rose 1021.0% year-over-year to 34.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 37.38% (up 700.0% YoY) and the FY2025 annual result came in at 39.79%, up 643.0% from the prior year.
- Operating Margin was 34.34% for Q1 2026 at Cytosorbents, up from 47.49% in the prior quarter.
- Across five years, Operating Margin topped out at 30.17% in Q3 2025 and bottomed at 111.17% in Q3 2022.
- A 5-year average of 64.2% and a median of 56.08% in 2024 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin tumbled 6273 bps — and 2024, when it soared 7144 bps.
- Cytosorbents' Operating Margin stood at 67.69% in 2022, then tumbled by 60 bps to 108.54% in 2023, then soared by 66 bps to 37.1% in 2024, then decreased by 28 bps to 47.49% in 2025, then climbed by 28 bps to 34.34% in 2026.
- Business Quant data shows CTSO's Operating Margin at 34.34% in Q1 2026, 47.49% in Q4 2025, and 30.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | -34.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.34% |
| Dec 31, 2025 | -47.49% |
| Sep 30, 2025 | -30.17% |
| Jun 30, 2025 | -37.59% |
| Mar 31, 2025 | -44.55% |
| Dec 31, 2024 | -37.10% |
| Sep 30, 2024 | -56.08% |
| Jun 30, 2024 | -40.38% |
| Mar 31, 2024 | -51.80% |
| Dec 31, 2023 | -108.54% |
| Sep 30, 2023 | -83.42% |
| Jun 30, 2023 | -69.62% |
| Mar 31, 2023 | -83.51% |
| Dec 31, 2022 | -67.69% |
| Sep 30, 2022 | -111.17% |
| Jun 30, 2022 | -98.37% |
| Mar 31, 2022 | -89.64% |
| Dec 31, 2021 | -88.68% |
| Sep 30, 2021 | -55.39% |
| Jun 30, 2021 | -40.96% |